Considering that antitumor T cells are often found at low frequencies in patient samples, we anticipate that our technology would pair well with therapeutic cancer vaccines containing one or a few known antigens, such as the KRAS or neoantigen vaccines currently in trials (75, 76). This evidence concerns the gene KRAS and cancer.